Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

© 2020 Wiley Periodicals LLC..

Hydroxychloroquine sulfate (HCQ) is being scrutinized for repositioning in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases. By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS-CoV-2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS-CoV-2 infection with laboratory confirmed negative cases. Out of 26 815 SARS-CoV-2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1215 (0.36%) out of 333 489 negative patients were receiving it chronically (P = .04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ has been 0.51 (0.37-0.70). Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Journal of medical virology - Vol. 93, No. 2 (2021), p. 755-759

Language:

English

Contributors:

Ferreira, António
Oliveira-E-Silva, António
Bettencourt, Paulo

Links:

Volltext

Keywords:

*Pre-Exposure Prophylaxis
4QWG6N8QKH
Adult
Aged
Antimalarials
Antiviral Agents
Arthritis, Rheumatoid
COVID-19
Chemotherapy < disease control
Drug Administration Schedule
Drug Repositioning
Economic reason < social science
Female
Humans
Hydroxychloroquine
Journal Article
Lupus Erythematosus, Systemic
Male
Middle Aged
Odds Ratio
Portugal
Public policy < social science
Registries
Retrospective Studies
SARS coronavirus < virus classification
SARS-CoV-2

Notes:

Date Completed 14.01.2021

Date Revised 14.01.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1002/jmv.26286

PMID:

32644224

PPN (Catalogue-ID):

NLM313129568